Purpose: To evaluate how well general practitioners (GPs) manage and respond to laboratory results for patients with diabetes mellitus (DM) and cardiovascular disease (CVD). Data sources: MEDLINE, CINAHL, Embase, EBM reviews, ProQuest and Scopus. Study selection: Peer-reviewed journal articles published between 2000 and 2015 that assessed GPs' management of laboratory results for patients with DM or CVD. Data extraction: Study design and demographics, laboratory tests and key findings relating to GP management of laboratory results were extracted from studies. Results of data synthesis: Thirteen articles were included, comprising seven studies which utilized surveys, four observational studies, one cohort study and one randomized controlled trial. Findings indicate that GPs often overestimate the risk of complications associated with DM and CVD based on laboratory results and have unrealistically high expectations regarding the precision of laboratory tests. Considerable variation existed in the use of repeat testing for diagnostic confirmation and in GPs' identification of the difference between two consecutive results required to indicate a change in patient condition. GPs also often failed to initiate appropriate treatment for patients with DM and CVD based on laboratory results. Feedback to GPs about their test ordering patterns and educational messages on laboratory results improved clinical outcomes. Conclusion: Evidence about how well GPs manage results and its impact on patient outcomes remains weak and inconclusive. This review identified a number of areas where interventions could support GPs to improve the interpretation and management of laboratory test results, including feedback to GPs and educational messages on test result reports.
Introduction
The past decade has seen a dramatic increase in the number of laboratory tests being ordered by general practitioners (GPs), with 25.5 million more tests ordered by Australian GPs in 2015 compared to 2005 [1] . In Scotland laboratory activity increased 74% between 2003 and 2010 [2] . While enhanced diagnostic technologies are a likely contributor to this increase [3] , there are persistent concerns about the substantial costs and risks associated with ordering unnecessary tests. Further, questions have been voiced about the capacity of GPs to accurately interpret and take appropriate clinical actions in response to the results of this vast amount of tests, a process herein referred to as test result management. Mismanagement of test results may lead to delayed, missed or incorrect diagnoses, inappropriate treatment and unnecessary additional tests and procedures [4] .
In primary care, the management of laboratory results is the responsibility of GPs [5] . Cardiovascular disease (CVD) and diabetes mellitus (DM) are two highly prevalent chronic conditions frequently managed by GPs [6, 7] . There are numerous clinical guidelines available to assist GPs in providing appropriate, evidence-based, laboratory testing for patients with these conditions [8, 9] , with the most common tests being blood glucose (BG) [10] , glycohemoglobin A1c (HbA1c) [10] , urine albumin (UA) [11] , albumin-creatinine ratio (ACR) [12] and international normalized ratio (INR) [13, 14] . Despite individual studies identifying variation in the way GPs manage the results of these tests, no review has synthesized this evidence to identify major problem areas in GPs management of test results and the extent to which various interventions can improve test result interpretation and management. The aim of this review was to synthesize the best available evidence of how well GPs manage laboratory results for patients with DM and CVD, as a step towards developing strategies to assist GPs in managing laboratory results.
Methods

Data sources
A systematic search of MEDLINE, CINAHL, Embase, EBM Reviews, ProQuest and Scopus was performed in May 2016 in accordance with PRISMA guidelines [15] . To ensure currency of evidence, peer-reviewed studies published between 2000 and 2015 were included if they investigated GPs management of BG, HbA1c, UA or ACR for patients with DM, or INR for patients with CVD. Articles were excluded if they were: not in English, case reports, abstracts, editorials or reviews. The search combined terms relating to: general practice, laboratory medicine, management and DM or CVD (Appendix 1).
Study selection
Titles and abstracts of all articles returned using these terms were independently reviewed (E.J.M. and J.L.) and sorted based on the predefined inclusion criteria. The full text of studies that met these criteria was then independently reviewed (E.J.M. and J.L.) and sorted based on the inclusion criteria. Inter-rater agreement of article inclusion was measured using the Kappa statistic [16] . Discrepancies were resolved through discussion between reviewers. References of included studies were hand searched for additional relevant studies. The search protocol is summarized in Fig. 1 , and registered on PROSPERO (PROSPERO 2016:CRD42016033470).
Data extraction
Management of laboratory results is defined as the interpretation of laboratory results and the provision of appropriate care based on these results. Studies were grouped by design: (a) surveys and (b) observational, cohort and randomized controlled trials (RCTs). Surveys were typically vignette case studies, while the other studies were performed using data from real patients. Demographics, laboratory tests and key findings were extracted (Table 1 ). Study quality was assessed using The Effective Public Health Practice Project (EPHPP) framework [17] , which is suitable for evaluating randomized and non-randomized studies and for use in systematic reviews [18] . Studies were given a rating of weak, moderate or strong based on their methodological strength.
Results
Thirteen articles met the inclusion criteria ( Table 1 ). The inter-rater agreement for article inclusion was 0.94 for titles and abstracts and 0.89 for full texts. Twelve (92.9%) were from Europe [11, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] and one from Australia [30] . There were seven surveys [11, [19] [20] [21] [22] [23] 30] , four observational studies [25] [26] [27] [28] , one cohort study [24] and one RCT [29] . Ten included patients with DM [11, 20, 22-27, 29, 30] and six patients with CVD [19, 21, 24, [27] [28] [29] . Four were published between 2000 and 2007 [21] [22] [23] 30] , with nine published between 2008 and 2015 [11, 19, 20, [24] [25] [26] [27] [28] [29] .
Critical appraisal of evidence
Of the seven surveys [11, [19] [20] [21] [22] [23] 30] , six were of weak quality (primarily due to low response rates, typically <50%) [11, [19] [20] [21] [22] [23] and one moderate [30] . Of the four observational studies [25] [26] [27] [28] , one was of weak quality (due to a lack of randomization and non-validated data collection methods [28] ) and three as moderate [25] [26] [27] . The cohort study and the RCT were both of strong quality [24, 29] .
Survey results
Results of the seven surveys [11, [19] [20] [21] [22] [23] 30] are reported under five themes: estimates of complications, critical differences (CDs) and analytical variation, repeat testing, target range and dosing, and diagnosis of secondary complications.
Estimates of complications
Two studies that asked GPs to estimate the risk of complications associated with CVD based on laboratory test results found that GPs overestimated these risks [19, 21] . 1547 Norwegian GPs were asked to estimate the risk of a bleed for a patient with a very high INR (5.9). The estimated risk was 75 times higher than the best estimate from the literature [21] . A similar survey of 2473 GPs from 13 countries found that GPs overestimated the risk of a stroke or bleed for a patient with an INR of 4.8 by two to three times, with no correlation between the risk of bleed and suggested changes in medication (r = −0.07) or time to a new INR measurement (r = 0.06) [19] . However, risk estimates were more accurate for GPs: prescribing medication to CVD patients at least once a week; familiar with using a clinical prediction rule to estimate the risk of stroke (specifically CHADS2); or using clinical decision support that assists risk estimates [19] .
Microalbuminuria is most commonly diagnosed by UA or ACR. Haller et al. [11] asked 800 GPs, 450 cardiologists and 450 diabetologists across five European countries to identify the risk between microalbuminuria and additional complications. While the associated risk of kidney damage was recognized by >93.8% of clinicians, associated risk of heart, eye, brain and vascular complications was recognized by <50% [11] .
CDs and analytical variation
Four surveys asked GPs to state the change in two consecutive laboratory results that would indicate a change in patient condition, termed the CD [20] [21] [22] [23] . Three studies found large intra and inter-country variation in CDs [21] [22] [23] . GPs also regarded smaller increases than decreases in INR and HbA1c as indicating a change in the patient's condition (21% vs. 24% and~6% vs.~11%, respectively) [21] [22] [23] . This was not the case for BG [22] and UA [20] , with increases and decreases regarded equally. Further, CDs for UA did not vary by reporting unit [20] .
Five studies used CDs to calculate the analytical imprecision expected by GPs [19] [20] [21] [22] [23] . All five found that GPs expected laboratory tests to have unrealistically low imprecision [19] [20] [21] [22] [23] . Furthermore, Skeie et al. [23] found that 98 of 444 (22%) Norwegian GPs would act on changes in HbA1c smaller than can be accurately determined using current hardware and assays.
Repeat testing
Two studies, one involving 1547 Norwegian GPs and one 2473 GPs from 13 countries, asked participants to state the recommended time to next INR test for patients with either a stable (2.3 and 3.3) or a very high (4.8 and 5.9) INR. They found that the median suggested time for both groups of patients corresponded with current guidelines (4 weeks and 7 days, respectively) [19, 21] . Further, the suggested time to next INR did not vary between GPs using clinical decision support or clinical experience [19] .
Three studies found large variations in the use of repeat testing to confirm a diagnosis [11, 20, 22] . One international study of 2538 GPs found a significant (P < 0.001) inter-country variation in the perceived importance of a repeat BG test after recording a BG value close to the target limit (mean 4.3/10-7.3/10) [22] . After positive detection of microalbuminuria, only 62% of 2078 Norwegian GPs would follow guidelines and employ a repeat test to diagnose microalbuminuria [20] , and only 21.5% of 800 European GPs knew that two of three tests had to be positive to diagnose microalbuminuria [11] .
Target range and dosing
When 1547 Norwegian GPs were asked to state the target INR range for patients with a mechanical heart valve or pulmonary embolism, only 29% and 63% identified the correct range for these two scenarios (2.5-3.5 and 2.0-3.0, respectively) [21] . A study of 2473 GPs from 13 countries found that for a patient with a stable INR of 2.3, 30-40% of Belgian and Hungarian GPs would change the medication dose when INR was still within the target range of 2.0-3.0, compared to <10% in other countries [19] . INR values >15% from the target range were tolerated by 50% of Danish GPs, compared to 5-30% in other countries. Finally, for a patient with a very high INR (4.8), there was large variation in the suggested change in medication during the first two days [19] , with no difference between GPs using clinical decision support or clinical experience.
Diagnosis of secondary complications
Thomas et al. [30] surveyed 348 Australian GPs to ascertain their ability to estimate kidney function. They compared GPs' estimates to values calculated from laboratory results in patients' medical records. They found a strong correlation (R 2 = 0.72) between GPestimated values of kidney function and those derived from laboratory results, with GPs able to identify impaired kidney function in >83% of cases.
Observational and interventional studies
Results of the four observational studies are reported under the theme of appropriateness of treatment, while results of the cohort study and RCT are reported under the theme of interventions to support result interpretation.
Appropriateness of treatment
While appropriateness of treatment can be influenced by a wide range of factors, including compliance, four observational studies investigated whether GPs delivered treatment in line with current guidelines based on laboratory results. A study of 1000 Russian CVD patients managed by GPs and cardiologists reported that 48.9% (n = 343) of patients with high cholesterol (>5 mmol/l) were not prescribed statins. Further, prescription rates did not vary between patients with cholesterol >5 or >6.2 mmol/l. Only 0.6% (n = 2) of patients with very high cholesterol (>6.2 mmol/l) were prescribed statins in high doses [28] . This is consistent with a study of 3215 Portuguese DM patients managed by GPs, which found that 42.6% (n = 1313) of those with high cholesterol (>135 mg/dl) were not prescribed statins [27] . A study of 2473 Danish DM patients managed by GPs found that 24% (n = 76) of patients with high HbA1c (>8%) had no new measurement or pharmacological treatment within 3 months, and that 25% of these received no therapy within a year [25] . This is consistent with a study of 14 120 Dutch DM patients managed by GPs which found that for unmedicated patients with repeated and incidental (found on one occasion) increased albuminuria, appropriate action was performed for only 16.5% (n = 51) and 14.3% (n = 42) of patients, respectively [26] .
Interventions to support result interpretation A cohort study of 8320 Danish DM patients, which was given an EPHPP rating of strong, provided GPs with weekly feedback on the proportion of patients with critical laboratory test results who were not medicated [24] . This intervention led to a significant (P < 0.001) reduction in the risk of a patient having a high HbA1C and not being on antidiabetic medication (absolute risk reduction of 1.4%), or having high cholesterol and not being prescribed statins (absolute risk reduction of 4.7%).
A cluster RCT of 8690 British DM patients investigated the impact of adding educational messages regarding glycaemic and cholesterol control to HbA1c test results, and regarding blood pressure (BP) control and foot inspections to ACR results. They found that these educational messages led to a statistically significant increase in the likelihood of further HbA1c tests (odds ratio 1.06) or foot inspections (incidence rate ratio 1.26), and a statistically significant decrease in diastolic BP (−0.62 mmHg) [29] . However, there was no statistically significant effect of these educational messages on: mean HbA1c, systolic BP and cholesterol; or the likelihood of HbA1c and cholesterol being within target range or further cholesterol tests. The authors postulate that this lack of effect was likely due to pre-trial values being close to the target range. This suggests that there may be a threshold in clinical performance beyond which educational messages have no or modest effects [29] . In contrast, the inclusion of educational messages about BP control was associated with a significant decrease in the likelihood of microalbuminuria patients having a BP within target range (odds ratio 0.88).
Discussion
This aim of this review was to investigate how well GPs manage laboratory results for patients with DM and CVD. Evidence of how well GPs manage results, and the impact on patient outcomes, is weak. However, the included studies highlight areas where improvements in test management could be focused and provide some potential strategies to assist GPs in this task.
Implications
The surveys included in this review suggest that GPs often overestimate the risk of complications associated with DM and CVD based on laboratory results [19, 21] . However, the observational studies indicate that GPs often fail to initiate appropriate treatment for patients with DM and CVD based on laboratory results [25] [26] [27] [28] , particularly related to pharmacological treatment initiation. This suggests a difference in work as imagined versus work as done [31] .
The surveys indicate that GPs generally expect laboratory tests to have unrealistically high precision [23] , which may stem from a lack of awareness of analytical and biological variation. They also show substantial variation in the use of repeat testing for diagnostic conformation [11, 20, 22] , potentially indicating a lack of adherence to evidence-based guidelines. Variation in CDs [21] [22] [23] may reflect an undue focus on the specific target value in certain countries. It may also indicate differences in practice [22] , caused by some GPs believing small changes in laboratory results are important while others do not act until changes are larger [20] . The lack of pharmacological treatment initiation found in the observational studies [25] [26] [27] [28] may indicate a belief among GPs that non-pharmacologically treated conditions are less severe, or differing opinions regarding the necessity and prioritization of certain actions, patient interactions and organization of care [26] . While there are many barriers to the implementation of research findings, overall these results suggest that increasing awareness of existing guidelines is an important step towards improving quality of care.
Interventions to assist GPs in managing test results
This review indicates that GPs may benefit from interventions designed to assist them in managing laboratory results, such as clinical decision support. The finding that risk estimates were more accurate for GPs using clinical decision support compared to those relying on clinical judgement demonstartes the benefit of such interventions [19] . These interventions should assist GPs in initiating appropriate treatment, with the safety and effectiveness of such systems previously demonstrated [32] [33] [34] [35] [36] . This review also suggests that providing feedback to GPs about their laboratory test ordering patterns [24] , and the addition of educational messages to laboratory results [29] , improves patient outcomes. Effective implementation of all, or some, of these strategies by laboratories or local health care providers should enhance patient care.
State of evidence relating to how GPs manage test results
The two interventional studies [24, 29] were the only studies that directly investigated the impact of GPs' test result management practices on patient outcomes. As a result, evidence relating to the effect of test result management on patient outcomes is weak. Therefore, further studies that directly measure the impact of GPs' test result management practices on patient outcomes are needed. However, the finding that 57% of the studies included in this review were of weak methodological quality highlights the need for future studies to ensure high scientific rigour. Further, surveys that ask GPs to make treatment decisions based on laboratory results, but which provide no reference range may, be more of a memory test than an accurate assessment of clinical reality, and may be of little scientific value.
Limitations
Reviews such as this lay an important platform for further studies investigating how GPs manage laboratory results, and provide a number of important recommendations. However, the results of the observational and interventional studies must be judged with caution, as pharmacological treatment may have been substituted for lifestyle interventions (such as exercise or diet modification) [25] . As such, a lack of pharmacological treatment is not always indicative of poor results management. Additionally, while the results of this review suggest that GPs may benefit from increased awareness of clinical guidelines, such guidelines have been disseminated extensively [25] . Therefore, alternative strategies to improve test result management are required, which also consider a range of other possible influencing factors, such as differing opinions between GPs regarding the necessity and prioritization of certain actions, patient interaction and organization of care [26] .
Conclusion
This review identifies a number of areas where the quality of laboratory result management and interpretation could be improved. Specifically, GPs may benefit from interventions designed to enhance: how they estimate risks based on laboratory results, their awareness of the need for repeat tests, and their understanding of the precision currently available from laboratory testing. Such strategies should enhance the likelihood of GPs initiating appropriate treatment. Further development and evaluation of strategies designed to support GPs during the management of laboratory results is also required, with improved feedback to GPs about their current practices, and the addition of educational messages to laboratory results, shown to improve patient outcomes. The quality of patient care may also be improved through increased awareness of current guidelines and the addition of clinical decision support for dosing, risk estimates, identifying correct target ranges and assisting with the identification of patients who require treatment initiation. These inter-related strategies can all be utilized in pursuit of improved GP result management and interpretation. However, the evidence surrounding how well GPs manage laboratory test results and the subsequent impact on patient outcomes remains weak.
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